MultiCell terminates license agreement with XenoTech

By Lisa Kerner

Erie, Pa., Feb. 6 - MultiCell Technologies, Inc. terminated its license agreement with XenoTech LLC prior to the end of the original seven-year term of agreement, according to a news release.

MultiCell had granted a license to XenoTech to practice inventions and use and sell products and services included in MultiCell's intellectual property related to immortalized human hepatic cells and cell lines.

MultiCell terminated the agreement due to the failure of XenoTech, with due notice, to cure various breaches within the time allotted by the agreement, the release said.

MultiCell engages in the development and commercialization of hepatic cells, cell lines and associated products for use in diagnostic and therapeutic applications. The company is based in Lincoln, R.I.

XenoTech is a drug metabolism research company based in Lenexa, Kan.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.